| Outcome Measures: |
Primary: Safety and tolerability change from baseline in laboratory assessments, Hematology, Clinical Chemistry, Urinalysis, Part A: Approximately 58 days and Part B: Approximately 38 days.|Safety and tolerability change from baseline in electrocardiaogram (ECG) reading, 12-lead ECG and continuous ECG monitoring., Part A: Approximately 58 days and Part B: Approximately 38 days.|Safety and tolerability change from baseline in fluid intake, urine output, and the number of micturations will be recorded., FPart A: Approximately 58 days and Part B: Approximately 38 days.|Safety and tolerability change from baseline in electrolytes, Blood electrolyte concentrations (Na, K, Cl, Ca, Mg and bicarbonate), Part A: Approximately 58 days and Part B: Approximately 38 days.|Safety and Tolerability change from baseline in creatinine clearance, creatinine clearance (24-hours \[h\]), Part A: Approximately 58 days and Part B: Approximately 38 days.|Composite of pharmacokinetic parameters of GSK189075A, GSK189074A, and GSK279782A, Area under the plasma concentration-time curve \[AUC(0 last)\], Area under the plasma concentration-time curve \[AUC(0-infinity)\], Maximum observed plasma concentration (Cmax), Time to maximum observed plasma concentration (tmax), Plasma elimination half-life (t1/2), Area under the plasma concentration-time curve for the metabolite \[AUCm(0-last)\]/ Area under the plasma concentration-time curve for the parent \[AUCp(0-last)\], and AUCm(0-infinity)/AUCp(0-infinity) ratios., Part A: up to 24 hours post dose for five periods. Part B: For 24 hours post dose for 3 periods. Collected at the following: pre-dose, and 10 min, 20 min, 30 min, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, , 8, 12, 16 and 24h post-dose.|Parts A and B: plasma glucose concentrations in healthy subjects, Part A: up to 24 hours post dose for five periods. Part B: For 24 hours post dose for 3 periods.|Parts A and B: Urine chemistry lab measurements, Urine samples for creatinine, glucose, and electrolytes (Na, K, Cl) measurements will be obtained., measurements will be obtained pre-dose, and over the following intervals: 0-2, 2-4, 4-6, 6-8, 8-12, and 12-24h during the dosing period.|Part B: Plasma glucose and insulin concentrations concentrations in subjects with type 2 diabetes mellitus following a 50g oral glucose challenge., On day -2 predose and at 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 10, 12 and 24h.|Safety and Tolerability as assessed by numbers of adverse events, number of adverse events collected during study, Part A: Approximately 58 days and Part B: Approximately 38 days.|Safety and Tolerability as assessed by change from baseline in vital sign measurements, Blood pressure and heart rate., Part A: Approximately 58 days and Part B: Approximately 38 days.|urine glucose concentrations in subjects with type 2 diabetes mellitus following a 50g oral glucose challenge., On day -2 predose and at 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 10, 12 and 24h. |
|
